Carbapenem-Based Antibiotics Market Size | Report 2021, 2028

The carbapenem-based antibiotics market size is expected to grow from US$ 3,964.57 million in 2021 to US$ 5,346.62 million by 2028; it is estimated to grow at a CAGR of 4.4% during 2021-2028.

Carbapenems are type of atypical β-lactam antibiotics that have wider antibacterial activity. Carbapenem-based antibiotics can cover many gram-positive, gram-negative aerobic, and anaerobic bacteria. Additionally, carbapenem-based antibiotics are stable to most β-lactamases. Hence, they are indicated as empiric monotherapy for various serious conditions, such as neutropenic infections and intra-abdominal infections.

The rising prevalence of gram-negative bacterial infections and the increasing production of generic drugs fuel the growth of the carbapenem-based antibiotics market. However, tedious and expensive process of antibiotic development restrains the market growth.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Carbapenem-Based Antibiotics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Market Insights
Rising Prevalence of Gram-Negative Bacterial Infections

Gram-negative bacterial infections, such as urinary tract infection (UTI), pneumonia, bloodstream infections, wound or surgical site infections, and meningitis, are commonly acquired by patients during their hospital stays. These infections are generally known as hospital-acquired infections (HAI). Infections such as UTI and pneumonia are common in patients admitted to intensive care units. According to the US National Healthcare Safety Network, 30% of HAIs are caused by gram-negative bacteria, ~45% are due to UTI, and ~47% are by ventilator-associated pneumonia (VAP). The prevalence of infectious diseases caused by gram-negative bacteria is rapidly increasing.

In addition, gram-negative bacterial infections are resistant to multiple drugs and have developed better resistance to available antibiotics. Antimicrobial resistance (AMR) has become a global threat to modern medicine. Therefore, constant monitoring of emerging trends is required for the clinical isolates. A group of researchers in Latvia, Europe, has studied the progression of AMR for different gram-negative bacteria. As per the research article published by them in the MDPI journal in June 2021, carbapenem-based antibiotics such as Meropenem and Ertapenem were the most effective against gram-negative bacteria, showing 3% and 5.4% resistance rates, respectively. These antibiotics are globally accepted as a treatment for gram-negative bacteria. Therefore, it is estimated that the high demand for carbapenem-based antibiotics is likely to continue in the coming years.

According to the Centers for Disease Control and Prevention (CDC), the COVID-19 pandemic led to the rise in HAI cases in 2020. Hospital admissions have grown globally, which has increased the risk of VAP as a secondary infection for COVID-19 patients. This has resulted in fueled demand for carbapenem-based antibiotics, which is aiding the market significantly.

Type-Based Insights

The carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is anticipated to register the highest CAGR in the market during the forecast period. The growing developments for carbapenem-based antibiotics are likely to drive the market growth in the future.

Indication-Based Insights

By indication, the carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is estimated to register the highest CAGR in the market during the forecast period. The uncertainty of bacterial infections propels the demand for carbapenem-based antibiotics, which is expected to drive the growth of market in the coming years.

Carbapenem-Based Antibiotics Market Regional Insights

The regional trends and factors influencing the Carbapenem-Based Antibiotics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Carbapenem-Based Antibiotics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Carbapenem-Based Antibiotics Market Report Scope

Carbapenem-Based Antibiotics Market Players Density: Understanding Its Impact on Business Dynamics

The Carbapenem-Based Antibiotics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Carbapenem-Based Antibiotics Market are:

1. Pfizer Inc.
2. Savior Lifetec
3. Sumitomo Dainippon Pharma Co., Ltd.
4. Merck & Co., Inc.
5. Gland Pharma Limited

Disclaimer: The companies listed above are not ranked in any particular order.

Distribution Channel-Based Insights

By distribution channel, the carbapenem-based antibiotics market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the carbapenem-based antibiotics market in 2021, and it is estimated to register the highest CAGR in the market during the forecast period.

 

Organic strategies, such as new product launch, is commonly adopted by companies to expand their product portfolios in the market. Moreover, the companies have implemented various inorganic strategies, such as mergers and acquisitions and partnerships. For instance, in May 2021, Gland Pharma Limited in association with Dr Reddy's Laboratories Ltd launched Ertapenem for Injection, 1 g/vial, a therapeutic equivalent to generic version of INVANZ (ertapenem for injection) for injection) 1 g/vial, which is approved by the US Food and Drug Administration (USFDA).

Company Profiles

• Pfizer Inc.
• Savior Lifetec
• Sumitomo Dainippon Pharma Co., Ltd.
• Merck & Co., Inc.
• Gland Pharma Limited
• Aurobindo Pharma Ltd
• DAEWOONG PHARMACEUTICAL CO.,LTD
• Iterum Therapeutics plc
• ACS Dobfar S.p.A
• Spero Therapeutics